Dr. Rizk on the Evolution of Surgery in Lung Cancer

Video

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Nabil P. Rizk, MD, MS, MPH, chief, Division of Thoracic Surgery, Hackensack University Medical Center, co-director, Thoracic Oncology, John Theurer Cancer Center, discusses the evolving role of surgery in lung cancer.

Historically, surgery and adjuvant chemotherapy were associated with significant morbidity in lung cancer, explains Rizk. ​Notably, only 50% of patients were able to tolerate adjuvant chemotherapy.

However, recovery for surgery has become much easier with the advent of minimally invasive and robotic approaches, Rizk adds. Now, patients can be released from the hospital within 1 ​to 3 days ​of undergoing a lobectomy, says Rizk. Then, patients are often eligible to start chemotherapy within 2 to 3 weeks.

As such, the argument that chemotherapy cannot be reliably administered in the adjuvant setting is no longer applicable with regard to minimally invasive surgery, Rizk concludes.

Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Debu Tripathy, MD
Changchun Deng, MD, PhD
Joaquim Bellmunt, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Bernard A. Fox, PhD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus